Phytocannabinoids are naturally occurring compounds found in the Cannabis sativa plant, with more than 100 different cannabinoids identified so far. According to this 2024 scientific review, CBD (cannabidiol) and THC (tetrahydrocannabinol) are the most extensively studied cannabinoids. Researchers note that CBD has shown potential anti-inflammatory, neuroprotective, and anxiolytic properties, while THC has demonstrated analgesic and antiemetic effects. The review also highlights growing interest in minor cannabinoids such as CBG, CBC, and CBN because of their unique pharmacological profiles and potential therapeutic applications.

The article explains that phytocannabinoids interact with the body’s endocannabinoid system (ECS), a network of receptors, enzymes, and naturally produced compounds that helps regulate many physiological processes. Beyond the ECS, cannabinoids may also influence neurotransmitter receptors, ion channels, and oxidative stress pathways. These complex interactions help explain why cannabinoids are being studied across a wide range of medical and scientific fields.

Researchers conclude that phytocannabinoids show significant promise for future therapeutic use, but emphasize that more clinical research is needed to fully understand their mechanisms, safety profiles, and effectiveness. The review identifies cannabinoids as an important area of ongoing medical research and suggests they may play a growing role in the development of future cannabinoid-based treatments.

Source

Blebea NM, Pricopie AI, Vlad RA, Hancu G. Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use. International Journal of Molecular Sciences. 2024;25(8):4204. https://pubmed.ncbi.nlm.nih.gov/38673788/